广告
加载中

相宜本草苦熬26年 “掉队之痛”一剂难愈

胡芳洁 2026-06-25 16:03
胡芳洁 2026/06/25 16:03

邦小白快读

EN
全文速览

本文梳理了老牌国货护肤品牌相宜本草26年从巅峰到掉队的发展历程,核心干货信息如下:

1. 品牌发展节点:相宜本草2000年创立,依托本草护肤理念快速发展,2013年销售额达到23亿元峰值,超过同期珀莱雅,先后两次启动A股IPO,分别在2014年、2024年终止,资本化之路历经12年仍未成功。

2. 当前发展现状:目前相宜本草主打科技本草转型,推出红景天美白、龙胆舒敏两大核心功效产品线,拿到了首个自主备案新原料,但入局功效护肤赛道太晚,头部品牌已经完成心智卡位,整体销量和竞品差距较大,还曾陷入违规添加有毒原料的争议,至今调查未有明确结论。

3. 消费提示:相宜本草当前品牌代言人覆盖不同群体,年轻化传播存在割裂,消费者选购时可多关注产品合规信息,理性看待品牌宣传的功效。

本文分析了相宜本草掉队的原因和转型尝试,能给本土美妆品牌提供多方面参考,干货总结如下:

1. 可吸取的失败教训:一是渠道战略误判,长期过度依赖KA渠道,错判CS渠道发展潜力,转型CS渠道时因政策不灵活、不同渠道价格冲突导致代理商压货,拓展失败;电商渠道收回自营太晚,错过2015-2020年的电商流量红利。二是定位踩监管红线,早期提出中草药护肤专家的定位,违反了化妆品禁止暗示医疗作用、禁止用专家名义宣传的监管要求。三是上市节奏预判失误,错过资本市场的窗口期。

2. 可参考的转型经验:当前契合功效护肤的消费趋势,主打科技本草,依托多年积累的本草护肤资产,联合高校做医研共创,布局新原料备案,走差异化竞争路线,方向符合市场需求,但要注意提前抢占消费者心智,避免入局太晚错失机会。

本文梳理了美妆行业的变迁和老牌品牌转型的经验教训,能给美妆卖家提供机会提示和风险参考,干货总结如下:

1. 行业需求与渠道变化:美妆行业渠道已经历经多轮迭代,早期KA渠道主导,后来CS渠道崛起,现在电商内容电商成为核心流量渠道,卖家需要紧跟渠道变化,不能固守传统旧渠道。当前消费需求以功效护肤为主,美白抗氧、敏感修护是核心增长方向,主打差异化的本草功效护肤仍有市场机会。

2. 风险提示:首先要合规经营,品牌和产品宣传不能触碰监管红线,不能做医疗功效暗示、违规使用专家名义宣传。其次拓展新渠道要提早布局,政策要灵活,还要协调好不同渠道的价格体系,避免不同渠道打价格战,导致代理商货品积压。

3. 运营提示:做品牌年轻化传播要保持受众定位统一,避免不同代言人覆盖的受众差异太大,导致品牌叙事割裂,无法建立清晰的消费者认知。

本文对相宜本草产品和发展的梳理,能给美妆相关工厂带来多方面启示,干货总结如下:

1. 产品生产设计需求方向:当下消费者越来越看重可验证的护肤功效,结合传统本草原料加现代生产科技的产品符合市场需求,比如相宜本草用植物细胞悬浮培养技术量产红景天原料,搭配冻干技术、微囊包裹专利技术提升功效,走医研共创的配方路线,都符合当前的需求趋势。

2. 商业机会:本草护肤赛道还有较大的差异化发展空间,品牌对道地原料开发、定制化成分提取、新技术应用的需求在不断提升,工厂可以提前布局相关产能和技术,对接品牌的差异化研发需求。

3. 数字化与电商转型启示:工厂需要配合品牌适配多渠道的供货需求,建立灵活的供应链体系,同时要严格遵守化妆品监管条例,把控原料和生产的合规性,帮助品牌避开合规风险,还要适配品牌线上化转型的小批量、多批次的供货需求。

本文梳理了当前美妆行业的发展情况和品牌痛点,能给美妆相关服务商提供不少参考,干货总结如下:

1. 行业发展趋势:美妆行业渠道一直在快速迭代,从KA到CS再到内容电商,功效护肤是当前主流发展方向,传统本草护肤品牌正在向科技结合本草的方向升级,整个行业监管持续趋严,对品牌合规性要求越来越高。

2. 客户核心痛点:老牌国货普遍存在传统路径依赖,渠道转型难,品牌心智老化,上市合规整改难度大,品牌年轻化传播容易出现定位错位的问题;新兴差异化品牌也需要医研合作对接、合规备案、品牌传播等多方面的支持。

3. 解决方案方向:服务商可以针对老牌国货推出渠道转型咨询、多渠道价格体系管控、品牌年轻化传播策划、合规整改辅导等服务,也可以针对本草类品牌提供原料研发合规备案、医研合作资源对接等服务,精准匹配品牌需求。

本文对美妆品牌发展的分析,能给美妆平台的招商运营带来不少启示,干货总结如下:

1. 品牌对平台的核心需求:不同类型的美妆品牌都需要适配的资源支持,转型中的老牌国货需要内容流量扶持来重新建立消费者认知,走差异化路线的新品牌需要平台提供心智培育的相关资源,帮助品牌快速起量。

2. 招商方向:平台可以重点关注有多年研发积累、走科技本草差异化路线的老牌国货,这类品牌本身有多年积累的品牌资产,只要转型方向正确,有很大的增长潜力,能给平台带来新的增长空间。

3. 运营管理与风险规避:平台要做好入驻品牌的合规管控,提醒品牌不要触碰监管红线,避免违规宣传;还要协调品牌的线上线下价格体系,避免价格冲突损害商家和平台的收益;另外要提前关注品牌的舆情风险,针对产品安全类争议提前做好应对预案,规避平台风险。

本文以相宜本草为典型案例,分析了老牌国货美妆的发展困境,对研究本土美妆产业发展有较高的参考价值,干货总结如下:

1. 当前产业新动向:国货美妆已经进入功效化、科技化的竞争阶段,传统本草护肤品牌开始探索传统中医理论结合现代科技的新发展路径,监管政策趋严重塑了品牌的定位逻辑,资本市场对美妆品牌的合规性要求也在不断提升。

2. 产业发展出现的新问题:很多有历史积累的老牌国货,存在渠道战略误判、上市节奏错失窗口、品牌定位跟不上监管政策变化、年轻化传播错位、科研成果转化慢、消费者心智卡位落后等问题,这些都是本土美妆产业升级过程中需要解决的新问题。

3. 研究方向启示:研究者可以围绕本土传统护肤品牌的转型路径、渠道变迁对品牌生命周期的影响、监管政策调整对美妆产业格局的改变、差异化本草护肤赛道的竞争逻辑等方向开展研究,这个案例能提供非常典型的研究样本。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

This article traces the 26-year development journey of Inoherb, a long-standing domestic Chinese skincare brand, from its peak performance to its current lag in the market, with key takeaways below:

1. Key development milestones: Founded in 2000, Inoherb grew rapidly on the back of its "herbal skincare" positioning, reaching a peak annual sales of 2.3 billion yuan in 2013—outperforming fellow domestic brand Proya that year. The brand has twice attempted an A-share IPO, scrapping the plans in 2014 and 2024 respectively, leaving its 12-year pursuit of capitalization still unrealized.

2. Current status: Inoherb is now pursuing a transformation to "technology-powered herbal skincare", launching two core efficacy-focused product lines: rhodiola-based brightening and gentian-based anti-sensitivity products. It has secured approval for the first self-developed new cosmetic ingredient it registered independently. However, it entered the efficacy skincare market too late, when leading brands had already locked in consumer mindshare, leaving its overall sales far behind key competitors. It was also embroiled in controversy over the illegal addition of a toxic raw material, with no clear conclusion from the investigation to date.

3. Consumer note: Inoherb currently works with multiple brand ambassadors targeting different consumer groups, leading to fragmented youth-focused branding. Consumers are advised to pay close attention to product compliance information and evaluate brand efficacy claims rationally when making purchasing decisions.

This article analyzes the reasons behind Inoherb's decline and its ongoing transformation efforts, offering multiple key takeaways for domestic Chinese beauty brands, as summarized below:

1. Key lessons to draw: First, Inoherb made critical misjudgments in its channel strategy: it relied excessively on traditional KA (key account) retail channels for years, misjudged the growth potential of CS (cosmetics store) channels. When it finally attempted to shift to CS channels, inflexible policies and cross-channel price conflicts led to massive overstock among distributors, and the expansion failed. It also waited too long to take back direct control of its e-commerce business, missing out on the 2015-2020 e-commerce traffic boom. Second, its original positioning as a "professional Chinese herbal skincare expert" crossed regulatory red lines, violating cosmetic advertising rules that prohibit implying medical effects and using "expert" titles in promotion. Third, it misjudged its IPO timeline and missed the optimal window for going public in the capital market.

2. Relevant takeaways from its transformation: Inoherb's current strategy of aligning with the consumer trend for efficacy skincare, focusing on technology-powered herbal skincare, leveraging its decades of accumulated herbal research assets, conducting joint research with universities, and investing in new ingredient registration to pursue differentiated competition, is aligned with current market demand. However, brands must prioritize locking in consumer mindshare early, as entering too late means missing out on growth opportunities.

This article sorts through the evolution of China's beauty industry and the lessons learned from legacy brand transformations, offering opportunity and risk insights for beauty sellers, as summarized below:

1. Industry demand and channel shifts: China's beauty industry has gone through multiple rounds of channel evolution: from KA channel dominance, to the rise of CS channels, to content-driven e-commerce becoming the core traffic channel today. Sellers must keep up with channel shifts instead of clinging to outdated traditional channels. Currently, consumer demand centers on efficacy skincare, with brightening/antioxidant and sensitive skin repair as the core growth areas. Differentiated herbal efficacy skincare still holds market opportunities.

2. Risk warnings: First, maintain compliant operations: brand and product marketing must not cross regulatory red lines, including implying medical effects or improperly using "expert" claims in promotion. Second, expand into new channels early, maintain flexible policies, and coordinate pricing across different channels to avoid price wars that leave distributors stuck with overstocked inventory.

3. Operations guidance: When executing youth-focused branding, keep audience positioning consistent. Working with ambassadors that target vastly different audiences will fragment brand narrative and prevent the formation of clear consumer recognition.

This article's analysis of Inoherb's development and products offers multiple insights for beauty product manufacturers, as summarized below:

1. Product design and development direction: Consumers increasingly value verifiable skincare efficacy today. Products that combine traditional herbal ingredients with modern manufacturing technology align well with market demand. For example, Inoherb uses plant cell suspension culture technology to mass-produce rhodiola ingredients, paired with freeze-drying technology and patented microencapsulation technology to boost efficacy, and follows a formula development route of joint medical-industrial research, all of which match current market demand trends.

2. Business opportunities: The herbal skincare track still has ample room for differentiated development. Demand from brands for authentic regional ingredient development, customized ingredient extraction and new technology application is growing steadily. Manufacturers can proactively build out relevant production capacity and technical capabilities to meet brands' demand for differentiated R&D.

3. Insights for digital and e-commerce transformation: Manufacturers need to adjust their supply chains to meet multi-channel delivery requirements from brands, build flexible supply chain systems. They must also strictly comply with cosmetic regulatory rules, control compliance of raw materials and production processes to help brands avoid compliance risks, and adapt to the small-batch, multi-batch delivery requirements brought by brands' online transformation.

This article sorts through current development trends and core pain points in China's beauty industry, offering key insights for beauty industry service providers, as summarized below:

1. Industry development trends: Beauty industry channels are rapidly iterating, shifting from KA to CS to content e-commerce. Efficacy skincare is the current mainstream development direction, and traditional herbal skincare brands are upgrading toward a model that combines technology with herbal ingredients. Industry regulation is also continuing to tighten, raising requirements for brand compliance.

2. Core pain points of clients: Long-standing domestic brands generally suffer from dependence on outdated business models, struggle to execute channel transformation, face aging brand perception, face high barriers to compliance adjustments for IPOs, and often end up with misaligned positioning when pursuing youth-focused branding. Emerging differentiated brands also need support across multiple areas, including connecting to medical research partnerships, compliance registration, and brand communications.

3. Direction for solution development: Service providers can develop customized offerings for legacy domestic brands, including channel transformation consulting, cross-channel pricing system management, youth branding planning, and compliance adjustment consulting. For herbal-focused brands, they can also offer services including compliance registration for ingredient R&D and connection to medical research partnership resources, to precisely match brand demand.

This article's analysis of Inoherb's development offers multiple insights for business attraction and operations management for beauty e-commerce platforms, as summarized below:

1. Core demands brands have from platforms: Different types of beauty brands all need tailored resource support. Transforming legacy domestic brands need content traffic support to rebuild consumer recognition, while new differentiated brands need platform resources for consumer mindshare cultivation to help them scale quickly.

2. Attraction priority: Platforms can prioritize recruiting legacy domestic brands with decades of R&D accumulation pursuing a differentiated technology-powered herbal skincare strategy. These brands already hold substantial accumulated brand equity, and have significant growth potential if their transformation direction is sound, which can bring new growth space for platforms.

3. Operations management and risk mitigation: Platforms must enforce compliance management for入驻 brands, remind brands to avoid crossing regulatory red lines and illegal advertising. They also need to coordinate online and offline pricing systems for brands to avoid price conflicts that hurt revenue for merchants and the platform. In addition, platforms should proactively monitor reputational risks for brands, and prepare pre-response plans for product safety controversies to mitigate platform risk.

This article uses Inoherb as a case study to analyze the growth dilemmas facing long-standing domestic Chinese beauty brands, offering high reference value for research on the development of China's domestic beauty industry, as summarized below:

1. New current industry trends: Domestic Chinese beauty brands have entered a stage of competition centered on efficacy and technology. Traditional herbal skincare brands are exploring new development paths that combine traditional Chinese medicine theory with modern technology. Tighter regulation has reshaped how brands position themselves, and capital markets are also raising increasingly high requirements for beauty brand compliance.

2. Emerging industry problems: Many legacy domestic brands with historical accumulation have faced common problems: misjudgment of channel strategy, missed IPO windows, brand positioning that failed to keep up with regulatory changes, misaligned youth marketing, slow commercialization of R&D results, and late mindshare positioning. These are all new problems that need to be solved during the upgrade of China's domestic beauty industry.

3. Insights for research directions: Researchers can conduct research on topics including transformation paths for legacy domestic skincare brands, the impact of channel evolution on brand lifecycle, how regulatory policy changes reshape China's beauty industry landscape, and the competitive logic of the differentiated herbal skincare track. The Inoherb case provides a highly typical research sample for these areas.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

2026年5月,上海浦东新区人民法院在微信公众号发布案例,广东某公司擅用“相宜”标识销售面膜等商品,构成商标侵权及不正当竞争,被判决停止使用侵权标识并赔偿原告相宜本草8.4万元。

相宜本草赢得了侵权官司,但在美妆行业竞技中,却步履蹒跚。

作为最具代表性的本草护肤品牌之一,相宜本草早在2013年销售额就达到23亿元峰值,超过珀莱雅等诸多本土品牌。

但遗憾的是,国货美妆持续崛起的浪潮中,相宜本草却日渐落后。不仅各类排行榜上不见其踪影,资本化运作也一再受挫。

反观珀莱雅,早在2017年便登陆A股,2024年营收破百亿。而相宜本草至今仍未叩开资本市场的大门。

昔日小弟已成大哥,相宜本草却依然奔走在转型路上。它到底做错了什么?

1

上市路空跑12年,相宜本草怎么这么难?

“我在单位里问了一圈了,都没有用相宜本草的,这个品牌还是比较小众。现在大家都用比较知名的品牌或大牌。”关熙(化名)对「创业最前线」表示。

关熙在四川某三线城市生活,近日,她询问了7、8个同事,发现没有人在使用相宜本草的产品。

而「创业最前线」近日走访北京某大型商超发现,相宜本草专属货架产品十分齐全,但购买者寥寥。超市导购表示,相宜本草适合送长辈,而且“超市利润薄,价格比专卖店更划算”。

关熙口中的“小众品牌”,曾经也是国货美妆的标杆之一。

相宜本草官网显示,相宜本草创始人封帅出生于医药世家,母亲是药剂师,外祖父杨继田曾是近代爱国名将冯玉祥的医生,曾在泰山脚下创办“博爱医院”。

2000年,相宜本草品牌创立,旨在秉承本草护肤理念。据澎湃新闻报道,相宜本草推出的第一款产品是宣称有“中草药功效”的面膜,产品推出后得到了部分消费者的认可。

2003年,相宜本草与上海中医药大学合作开启本草护肤研究。2012年,相宜本草研发中心和上海宝山工厂竣工并投入使用。

发展中,产品矩阵从早期的面膜,扩大到护肤全品类,品牌定位也一度从“面膜专家”转变为“本草护肤专家”。

2012年左右,是相宜本草的巅峰时期。

据华福证券援引欧睿咨询数据,2012年相宜本草以2.1%的市占率在国内护肤品市场排名第九。2013年,相宜本草销售额达到23亿元,同期珀莱雅营收仅为14.3亿元。

业绩快速增长,相宜本草也开启了资本化进程。2012年,相宜本草递交招股书,拟登陆上交所。

但遗憾的是,由于相宜本草所倚重的商超渠道(KA渠道)环境恶化、因虚假宣传而被工商处罚,且与早期投资方今日资本“交恶”……种种因素之下,相宜本草并未如愿登陆资本市场,2014年主动终止IPO。

直到2022年11月,相宜本草与中金公司签署上市辅导协议,再次启动A股IPO计划。

然而,过去的十年,市场格局早已天翻地覆,一大批国货美妆品牌在功效护肤的浪潮中,依托抖音等内容电商的流量红利,快速崛起或完成转型。而失去头部位置的相宜本草,市场影响力已大不如前。

更不利的是,2022年全国化妆品零售总额同比下滑了4.5%,近10年来首次出现负增长。

?此外,相宜本草经销模式营收占比过高、经销商数量众多且分散等问题,也在上市辅导中逐渐暴露出来。

内外交迫之中,相宜本草于2024年再次终止上市计划。曾经拿着一手好牌的相宜本草,却在发展中接连遇阻。

2

渠道与市场格局预判,两个关键失误

实际上,相宜本草主打的护肤理念,与市面上常见的草本护肤、植物护肤,有明显区别。

据公开资料,“本草”是中药的统称或中药典籍的名称,“本草”护肤依托中国传统医学(中医)理论,强调配伍(多种原料复配)和道地原料(产自特定地域的中药材)等。这与相宜本草官网企业简介吻合。

而“草本”护肤,更偏向于成分论,主要关注植物提取物中含有的具体成分。

相对于草本护肤的简单直接,本草护肤在认知上存在天然门槛。但硬币的另一面,前期的相宜本草使用“中草药护肤”作为差异化内核。

2017年,曾于2014年辞任的相宜本草前总裁严明回归公司(后又于2020年离职),并进行一系列变革,明确提出“中草药护肤专家”定位,意图以独特优势,在挑战中谋求新增长。

这一定位虽然通俗易懂,却踩中了监管“雷点”。2020年《化妆品监督管理条例》禁止化妆品暗示医疗作用,2022年《化妆品标签管理办法》禁止利用“专家”名义作证明或推荐。

监管趋严,或许正是相宜本草从“中草药护肤专家”转向“科技本草”定位的核心动因之一。

但定位难题只是一方面,相宜本草真正的困境,在于渠道战略失误与市场格局误判。

错失美妆专营店CS渠道、电商渠道增长红利,正是相宜本草在渠道上的一个关键失误。

与珀莱雅、韩束等从CS渠道发展起来不同,相宜本草从创立之初,就瞄准大型连锁商超KA渠道。当时,国内商超渠道刚刚起步,相宜本草随着商超渠道扩张而快速成长。

招股书显示,2009-2011年,相宜本草营业收入3.77亿元、7.5亿元及13.35亿元,几乎以每年翻一倍的速度增长。2011年,KA渠道销售额10.18亿元,占比高达76%;CS渠道仅1.19亿元,占比约9%。

意气风发的相宜本草在2012年递交了招股书。但2011年,其一向倚重的KA渠道,已经开始发生微妙的变化。

天风证券针对化妆品行业的研究报告显示,2011-2016年,百货、KA渠道(超市、大卖场)份额显著下降,KA渠道由34.1%下降至26.9%;而电商和CS渠道显著上升,CS渠道由15.8%提升至18.2%。

到了2018年,电商、CS渠道跃升为化妆品市场排名前两位的渠道,占比分别为29%、27%。

严明也曾表示,公司决策层首先就对CS渠道判断有误,当时他们认为商超的发展和下沉到三线以下城市才是趋势,下沉市场的CS专营店肯定会受到冲击而衰落。

但事实证明,CS渠道发展远远超出了相宜本草预期。意识到问题所在的相宜本草,开始寻求解决CS渠道问题,提升收入占比。

2015年初,相宜本草推出针对CS渠道的“金相宜”系列。创始人封帅也一改以往低调姿态,高调地宣布2015年CS渠道将会成为公司渠道拓展重心。

但CS渠道进展并不如人意。据青眼、未来迹等报道,由于动销难落地、政策不灵活,相宜本草大促很难做,导致代理商货品积压;此外,KA渠道活动门槛低、力度大,使得CS渠道很难与之竞争。

在战略摇摆和市场变迁中,2015年,相宜本草销售额已大幅下滑至15亿元左右,比巅峰期23亿元下滑了三成多。

而电商渠道的运营,相宜本草反应也较为迟钝。

早在2007年,相宜本草就布局淘宝渠道,由丽人丽妆进行电商代运营,直到2020年才收回天猫旗舰店代运营权,转为品牌自营。

虽然拿回了主动权,但行业普遍认为,相宜本草这一步已经稍显迟缓,错过了2015-2020年间电商高速发展的流量红利期。

在上市时机的预判上,据媒体报道,相宜本草在2017年左右开展系列改革的同时,计划在2020年重返资本市场。然而,2020年之后,疫情爆发、内容电商崛起,极大影响着美妆市场格局。若等做好准备再行动,可能已经错过了窗口期。

3

红景天、龙胆挑大梁,靠“科技本草”能否翻身?

虽在资本与渠道层面屡屡受挫,但相宜本草并非没有突围的筹码。

相宜本草发展26年所积累的品牌资产,正被重新梳理,装入一个名为“科技本草”的新故事中。

本草护肤是品牌传承,而与现代科技的结合,则契合当下对可验证的护肤功效的追求。高山植物红景天,在其中扮演着关键角色。

围绕红景天提取物,相宜本草研发出抗氧美白王牌红景天系列,并从早期抗氧焕亮,进阶到如今的精准对抗“压力黄”,通过一步步放大“红景天”护肤潜能,来强化其科研叙事。

其中,明星单品“红景天焕白精华液”中添加了大花红景天提取物,且核心成分红景天苷含量大于10%,还复配藏菖蒲、云茯苓等合计13种本草,结合冻干技术、微囊包裹专利技术、导入元专利技术来保持活性、促吸收,实现“内源去黄、淡斑美白”功效。

同时,品牌还联合上海中医药大学在SCI期刊上发表研究成果,提出红景天苷抑制“压力黄”新机理并应用于新升级的相宜本草焕白淡斑修护乳霜(氧白霜)产品中。

2026年3月,相宜本草完成了首个自主备案新原料“大花红景天愈伤组织溶胞产物滤液”,通过植物细胞悬浮培养技术,实现红景天原料的可持续量产。

针对敏感肌护理的龙胆系列,则是相宜本草以医研共创推进的另一大核心产品线。

大单品“龙胆修护霜”,配方灵感来自于上海中医药大学附属龙华医院的临床舒敏方,包含专研龙胆复合精萃,复配藏地植物小分子PDRN,人源重组17型胶原蛋白等,结合仿生修护专利技术,实现褪红热、深修护功效。

这套“科技本草”叙事逻辑完整、路径清晰,美白抗衰、敏感修复也精准契合主流功效护肤需求。

但问题在于,相宜本草来得太晚了。

截至2025年10月,贝泰妮已备案17款新原料,植物医生今年5月也备案两款新原料;当龙胆修护霜2026年全新上市时,薇诺娜已在敏感肌赛道建立近乎垄断的市场认知。

功效护肤头部玩家已完成科研与心智卡位,而“科技本草”能否穿透消费者认知,仍是未知数。

红景天焕白精华液已上市近10年,截至目前天猫旗舰店销量7万+,排名第一。但红景天精华液的热销,并没有带动同系列水乳、面霜销量同等上涨,销量均仅1万+。

对比植萃美白护肤品牌谷雨,其雪肌焕白水乳套装销量为40万+,美白奶罐面霜销量20万+,与相宜本草不在一个量级。(编者按:上述销量统计时间均为2026年6月中旬,且仅为天猫渠道,不代表品牌整体销量。)

此外,相宜本草还曾陷入“毒原料”争议。2024年底,有“吹哨人”爆料公司产品违规添加有毒中草药“犁头尖”,公司发声明否认并报案,监管部门介入调查,但至今尚无结论公布。

就此,「创业最前线」致函相宜本草方面,试图了解目前调查进展情况以及公司是否已收到阶段性或正式的结论,但截至发稿前未获回复。

「创业最前线」注意到,在持续线上化转型中,相宜本草也试图借助代言人合作推动品牌年轻化与销量提升。

2025年8月,其官宣流量明星张凌赫为面膜代言人;2026年1月,官宣青年演员常华森为品牌大使,同月还官宣香港风水师麦玲玲为红运推荐官。

代言人虽按产品线和传播主题选定,但从消费者角度来看,流量明星、演员和风水大师所面对的受众存在明显区隔,相宜本草的年轻化叙事或存在割裂风险。

毫无疑问,相宜本草还需要更高效地将科研沉淀转化为可感知的品牌认知,“科技本草”这一剂良方才有可能缓解“掉队之痛”。而这考验的不仅是研发能力,更是品牌和年轻消费者的沟通能力。

“科技本草”或许是一条正确的路,但问题是,留给相宜本草追赶的时间还有多少?

(注:本文部分阐述系客观援引企业产品的对外宣传口径,不代表实际功效;化妆品仅为皮肤护理产品,不具备疾病治疗、内调功效,请广大读者理性消费。)

注:文/胡芳洁,文章来源:创业最前线(公众号ID:chuangyezuiqianxian),本文为作者独立观点,不代表亿邦动力立场。

文章来源:创业最前线

广告
微信
朋友圈

这么好看,分享一下?

朋友圈 分享

APP内打开

赞 +1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0